Environmental Mutagenesis & Genomics Society
49th Annual Meeting, San Antonio, Texas
September 22-26, 2018 - Hyatt Regency San Antonio
Maintaining Genomic Integrity in the Face of Environmental Insult
EMGS 2018
Meeting Microsite
Access your registration information, the abstracts, view meeting attendees and more on the event microsite! Go to https://www.emgs-us.org/event/3/ and login using your email and registration code. You can find your registration code on your confirmation email and also on the back of your badge.
Welcome
The EMGS welcomes members and attendees from across the US and around the world. Our diversity is essential to our success, and as your national professional society, we are committed to providing a safe and supportive forum for the communication of world-class science. The EMGS Diversity and Inclusion committee sends a special welcome to members of the LGBT community. Please reach out to any member of the EMGS Diversity and Inclusion Committee with your comments or concerns.
View Past Annual Meeting abstracts.
EMGS Local News Publicity:
Flint Water Whistleblower to S.A. Audience "Thousands of Flints Out There"
Public Invited to Hear Renowned Whistleblower in Flint Water Crisis
Announced in: San Antonio, TX
2018 EMGS Annual Meeting
Maintaining Genomic Integrity in the Face of Environmental Insult
Wednesday, September 26, 2018
7:00- 8:15 AM
Committee Meeting
Hollaender Outreach
Pecos Room
Committee Meeting
Diversity and Inclusion
Frio Room
Committee Meeting
Publication Policy
Nueces Room
8:30- 9:30 AM
Keynote 5
How a Carcinogen Works: Skin Cancer from the Ground-State Up
Douglas Brash Yale University
Regency West
10:00- 12:00 PM
Symposium 12: Mechanisms of UV-Mutagenesis: Where the Rubber Meets the Road During Environmental Carcinogenesis
Chairpersons: William Kaufmann and Shobhan Gaddameedhi
10:00-10:05
Introduction
10:05-10:25
Regulation of the UV DNA Damage Response in Aged Versus Young Skin
Michael Kemp, Wright State University
10:25-10:45
The impact of circadian clock disruption on solar UVB-induced DNA damage signaling in SKH-1 hairless mice
Panshak Peterson Dakup, Washington State University
10:45-11:05
Pathological Activation of Translesion DNA Synthesis During Carcinogenesis
Cyrus Vaziri, U of North Carolina
11:05-11:25
Chronic formation of 8-oxo-guanine at telomeres triggers chromatin bridges and genomic instability
Elise Fouquerel, University of Pittsburgh
11:25-11:45
Clastogenic consequences of replication stalling
William Kaufmann, Asystbio Laboratories LLC
11:45-12:00
Questions and Discussion
Regency West 4/5
Symposium 13: Quantitative Analysis of Genetic Toxicity Dose-Response Data for Risk Assessment and Regulatory Decision-Making
Chairpersons: Paul White and Andreas Zeller
10:00-10:25
Genetic toxicity as a bone fide toxicological endpoint for regulatory evaluations and decision making.
Bob Heflich, NCTR, USFDA
10:25-10:50
Quantitative dose-response analysis for potency ranking and read across of genotoxic substances
Paul White, Health Canada
10:50-11:10
Leveraging Cell Micropatterning Technology for Rapid Cell-Based Assessment of Chemical Toxicity
Bevin P. Engelward, Massachusetts Institute of Technology
11:10-11:35
Critical Effect Sizes for Genetic Toxicity Endpoints. How Do We Determine How Much Is Too Much?
Andreas Zeller, Roche, Basel
11:35-12:00
Human Health Risk Assessment of Genotoxic Carcinogens: Genetic Toxicity Data Versus Carcinogenicity Data
Nikolai Chepelev, Health Canada
Regency West 6
Platform 6: Genetic Toxicology
Chairpersons: Malathi Banda and Kelly Harris
10:00-10:05
Introduction
10:05-10:20
3Rs Friendly Study Design Facilitates Combination Rat Liver Micronucleus, Blood Micronucleus, and Pig-a Assays: Proof-of-Concept with Benzo[a]pyrene, Cyclophosphamide, Diethylnitrosamine, Hydroxyurea, and Quinoline
Stephen D. Dertinger, Litron Laboratories
10:20-10:35
Are All Ames Strains in the OECD Mutagenicity Test Guideline 471 Useful and Necessary? An Analysis of Large Mutagenicity Data Sets for the IWGT
Kevin Cross, Leadscope
10:35-10:50
Bacterial Reverse Mutation (Ames) Test: Time to Revise OECD Test Guideline 471?
Leon F, Stankowski Jr, Charles River Laboratories
10:50-11:05
Establishing A Partial Adverse Outcome Pathway (AOP) Describing Oxidative DNA Damage Leading To Micronuclei Induction
Eunnara Cho, Health Canada
11:05-11:20
In vitro genotoxic potency comparison of 15 plant-based pyrrolizidine alkaloids using metabolically competent HepaRG cells
Ashley Allemang, The Procter & Gamble Company
11:20-11:35
Quantitative analysis of genotoxicity of four nitroxides in mouse lymphoma cells
Xiaoqing Guo, National Center for Toxicological Research
11:35-11:50
The ToxTracker assay as a tool for mechanism-based (geno)toxicity screening of nanoparticles and read across
Giel Hendriks, Toxys
11:50-12:00
Questions and Discussion
Regency East 3
12:00- 1:30 PM
Committee Meeting
Finance and Fundraising
Pecos Room
Committee Meeting
Committee Meeting
SIG Chairs
Nueces Room
12:30- 1:30 AM
Informational Session
Strategies to Enhance Visibility of Scientific Publications
Kassie Stovell, Publication Manager at Wiley
Regency West 4/5
1:30- 3:30 PM
Symposium 14: Controversies and Challenges in Risk Assessment: Examples of Regulatory Decision Making
Chairpersons: Rosalie Elespuru and Catherine Gibbons
1:30-2:00
Insights on Genetic Toxicology, Cancer Risk, and More From 25 Years At The FDA
Rosalie K. Elespuru
2:00-2:30
Mutagens and carcinogens in Japanese food: evolution of prioritized risk
Masamitsu Honma
2:30-3:00
Evolution Of Regulatory Concern For Acrylamide, A Germ Cell Mutagen And Environmental Carcinogen: From Electrophoresis Reagent To Coffee And French Fries
Kerry Dearfield
3:00-3:30
Regulatory approaches in Europe: what is important, and what might change in the future viewed from a “clean sheet”
Jan van Benthem
Regency West 6
Symposium 15: Non-Clinical Applications of Next-Generation Sequencing for Mutation Detection and Cancer Risk Assessment
Chairpersons: Mark Fielden and Lizzie Ngo
1:30-2:00
Detection of Rare and Subclonal Mutations by Next-Generation Sequencing
Jesse Salk, TwinStrand Biosciences Inc.
2:00-2:15
Application of Duplex Sequencing™ for In Vivo Mutation Detection
Robert R. Young, BioReliance Corporation
2:15-2:45
Assessing Cancer Driver Mutations as Biomarkers of Cancer Risk by Error-Corrected NGS
Barbara Parsons, National Center for Toxicological Research
2:45-3:00
The mutational landscape of lacZ and how it reveals mutational fingerprints associated with human cancer signatures
Francesco Marchetti, Environmental Health Science and Research Bureau, Health Canada
3:00-3:30
Linking mutational spectra of chemical carcinogens to the mutational patterns seen in human tumors
John Essigmann, Massachusetts Institute of Technology
Regency West 4/5
Platform 7: DNA Repair 2
Chairpersons: Aishwarya Prakash and Bret Freudenthal
1:30-1:50
A Pre-Catalytic Noncovalent Step Governs DNA Polymerase β mutator activity
Khadijeh Alnajjar, Yale University
1:50-2:10
Exploring the mechanism of ATR/Chk1-dependent replication initiation control in undamaged cells
Tatiana Moiseeva, University of Pittsburgh
2:10-2:30
FANCJ Separation of Function Mutant Distinguishes its Role in Interstrand Cross-link Repair Versus Response to Replication Stress
Sanket Awate, NIH Biomedical Research Center
2:30-2:50
Functional interplay between DNA repair and DNA damage response in oxidative stress
Steven Cupello, UNC Charlotte
2:50-3:10
Single strand break signaling by APE2
Yunfeng Lin, UNC Charlotte
3:10-3:30
Molecular insight into APE1 mutations associated with human disease
Amy Michelle Whitaker, University of Kansas Medical Center